Metallodrugs
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 November 2012) | Viewed by 325
Special Issue Editor
Special Issue Information
Dear Colleagues,
The discovery of cisplatin as a potent antitumour agent in the mid-60s heralded a new era of anticancer research based on metal-based complexes. Today, platinum-based drugs constitute some of the most widely applied chemotherapeutics in clinical use. Their success and relevance in modern medicine continue to galvanise the community into the search for better and more effective metallodrugs, particularly those based on other metal centres, against a backdrop of an expanding scope of diseases and ailments. This surge in research activity has been coupled with exciting new opportunities afforded by the discovery of new therapeutic targets through rational drug design over the past decade. Beyond classical DNA-damaging cytotoxic agents, there has been increasing interest in exploiting metallodrugs as modulators of specific cellular pathways for therapeutic intervention. This special issue aims to provide the readers highlights of these new developments in this broad subject covering the entire spectrum of discovery, validation and compound testing.
Dr. Wee Han Ang
Guest Editor
Keywords
- metallodrugs
- metallopharmaceuticals
- bioinorganic compounds
- bioorganometallic compounds
- metal-based drugs
- metallocomplexes
- chemotherapeutics
Related Special Issues
- Metal-Based Drugs in Pharmaceuticals (1 article)
- Metal-Based Drugs: Updates and Perspectives in Pharmaceuticals (14 articles)
- Selective Chelators for Metals on Cells and Cancer Chemotherapy in Pharmaceuticals (1 article)
